Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.53 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20516443 | 1.00 | GAA (0.54) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7624222 | 0.80 | GAA (0.46) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20516428 | 0.79 | CES2 (0.42) | GAAHDAC1HDAC6 | |
| SCHEMBL20516425 | 0.79 | CES2 (0.42) | GAAHDAC1HDAC6 | |
| SCHEMBL7623786 | 0.79 | PLA2G10 (0.47) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL11267920 | 0.79 | PLA2G10 (0.60) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12408230 | 0.79 | PLA2G10 (0.60) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6399100 | 0.79 | GAA (0.54) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6400213 | 0.79 | GAA (0.54) | GAAPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6106268 | 0.79 | GAA (0.54) | GAAPOLBCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336709-B2 | Lp-PLA2 inhibitors | ABIDE THERAPEUTICS, INC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180282288-A1 | LP-PLA2 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282288-A1 | LP-PLA2 INHIBITORS | PLA2G12A, PLA2G12B, PLA2G4B | GAA 399/4885POLB 2789/4885CYP1A2 1522/4885 |
| US-10336709-B2 | Lp-PLA2 inhibitors | PLA2G12A, PLA2G12B, PLA2G1B | GAA 393/4885POLB 2676/4885CYP1A2 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.